journal
MENU ▼
Read by QxMD icon Read
search

Current Hematologic Malignancy Reports

journal
https://www.readbyqxmd.com/read/28626849/equal-treatment-and-outcomes-for-everyone-with-multiple-myeloma-are-we-there-yet
#1
REVIEW
Sikander Ailawadhi, Kirtipal Bhatia, Sonikpreet Aulakh, Zahara Meghji, Asher Chanan-Khan
Multiple myeloma treatment has changed tremendously over recent years leading to overall improvement in patient outcomes. With therapeutic advancements, patient care has become increasingly complex and variability is seen in healthcare delivery as well as outcomes when various patient subgroups are analyzed based on sociodemographic factors. It is imperative to understand this variability so that while overall the outcomes get better, specific focus is placed on subgroups that may remain disadvantaged and may not be able to fully access the advancements in therapeutics...
June 19, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28573497/therapeutic-options-for-aggressive-t-cell-lymphomas
#2
REVIEW
Jennifer K Lue, Anna Kress, Jennifer E Amengual
T-cell lymphomas (TCL) are a rare, heterogeneous group of non-Hodgkin lymphomas associated with very poor prognosis with standard cytotoxic chemotherapy. Epigenetic-based therapy, such as with histone deacetylase inhibitors, was initially discovered to be efficacious in TCL. In recent years, our understanding of the mechanisms driving T-cell lymphomagenesis has validated the use of epigenetic-based drugs and has also led to the development of novel agents with promising efficacy in pre-clinical and early clinical trials...
June 1, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28573496/patient-and-caregiver-adjustment-to-hematopoietic-stem-cell-transplantation-a-systematic-review-of-dyad-based-studies
#3
REVIEW
Shelby Langer, Christine Lehane, Jean Yi
PURPOSE OF REVIEW: The aims of this study were to identify and systematically evaluate studies published from 2005-2017 that took a dyadic approach to assessing or intervening upon hematopoietic cell transplant (HCT) recipients and their informal caregivers. RECENT FINDINGS: Our search yielded 20 studies. Regarding sample demographic characteristics, most participants were Caucasian and most caregivers were related to the patient by marriage. Regarding design characteristics, 18 studies were quantitative and two were qualitative; five were cross-sectional, ten were longitudinal, one was experimental, and four were interventional...
June 1, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28567524/patterns-of-care-and-survival-for-elderly-acute-myeloid-leukemia-challenges-and-opportunities
#4
REVIEW
Abhishek A Mangaonkar, Mrinal M Patnaik
PURPOSE OF REVIEW: Acute myeloid leukemia (AML) is a disease of the elderly, with a median age of diagnosis in the sixth decade of life. Mortality has declined over the last few years, but this impact is apparent only in the young, fit AML population. Outcomes for the elderly remain poor, with less than 20% 5-year overall survival rates. Hence, there is an unmet need to identify treatment strategies to maximize benefit in this age group. RECENT FINDINGS: Elderly AML is a difficult entity to treat due to both disease and patient-related factors...
May 31, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28534144/coordination-of-care-in-survivorship-after-treatment-of-hematological-malignancies-the-journey-is-not-over-yet
#5
REVIEW
Catherine J Lee, Lori S Muffly
The number of adult survivors of hematologic malignancies is steadily growing. This population is at moderate to high risk for cancer survivorship issues including physical and psychosocial sequelae of intensive cancer therapies. Although cancer survivorship is a growing field in pediatric and solid tumor oncology, survivorship care and research has often been overlooked in the hematologic malignancies. In this review, we focus specifically on survivorship issues related to adult patients with hematologic malignancies and provide commentary on the role of cancer survivorship, proposed survivorship care models, and the economic and health policy obstacles associated with moving the cancer survivorship field forward in this very important patient population...
May 22, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28497317/role-of-radiation-therapy-in-the-treatment-of-hodgkin-lymphoma
#6
REVIEW
Victor J Gonzalez
Radiation therapy has historically been the pillar of curative treatment for Hodgkin lymphoma (HL). With improved efficacy of systemic therapy and the ever-increasing recognition of treatment-related morbidity in long-term survivors, the role of radiotherapy has evolved significantly. Modern combined modality therapy (CMT) with multi-agent chemotherapy followed by involved site radiation therapy (ISRT) to initially involved sites of disease remains the gold standard for the majority of patients with HL. Reduction of long-term treatment-related toxicity has become the major driver in clinical trial design for early-stage HL while improved disease-specific survival remains the goal in patients with more advanced and unfavorable disease...
May 11, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28488185/where-do-the-new-drugs-fit-in-for-relapsed-refractory-hodgkin-lymphoma
#7
REVIEW
Niloufer Khan, Alison J Moskowitz
The standard approach for relapsed or refractory (rel/ref) Hodgkin lymphoma (HL) following frontline treatment failure is salvage therapy followed by consolidation with high-dose therapy and autologous stem cell transplant (HDT/ASCT). While this overall treatment paradigm has been in place for several decades, recent studies have aimed to improve the efficacy and tolerability of salvage therapies by incorporating newer drugs, such as brentuximab vedotin (BV) and checkpoint inhibitors. Following HDT/ASCT, survival is improved due to the availability of BV and the checkpoint inhibitors, nivolumab and pembrolizumab; however, for patients responding to checkpoint inhibition, the appropriate length of treatment and the role of allogeneic stem cell transplant are unclear...
May 9, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28478586/a-review-of-autologous-stem-cell-transplantation-in-lymphoma
#8
REVIEW
Umar Zahid, Faisal Akbar, Akshay Amaraneni, Muhammad Husnain, Onyee Chan, Irbaz Bin Riaz, Ali McBride, Ahmad Iftikhar, Faiz Anwer
PURPOSE OF REVIEW: Chemotherapy remains the first-line therapy for aggressive lymphomas. However, 20-30% of patients with non-Hodgkin lymphoma (NHL) and 15% with Hodgkin lymphoma (HL) recur after initial therapy. We want to explore the role of high-dose chemotherapy (HDT) and autologous stem cell transplant (ASCT) for these patients. RECENT FINDINGS: There is some utility of upfront consolidation for-high risk/high-grade B-cell lymphoma, mantle cell lymphoma, and T-cell lymphoma, but there is no role of similar intervention for HL...
May 6, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28470380/the-management-of-lymphoma-in-the-setting-of-pregnancy
#9
REVIEW
Chelsea C Pinnix, Therese Y Andraos, Sarah Milgrom, Michelle A Fanale
The diagnosis of lymphoma in pregnant patients poses a therapeutic challenge necessitating consideration of the developing fetus without compromise of therapy with curative potential for the mother. The decision to initiate therapy during pregnancy is heavily influenced by fetal, maternal, and disease-related factors, of which the most influential are the trimester at diagnosis, the stage, and aggressiveness of the disease and the presence of life-threatening symptoms. Recent data suggest that deferral of therapy until after the first trimester is desirable if it is perceived that postponement of therapy will not compromise maternal outcome...
May 3, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28439761/small-molecule-inhibitors-in-chronic-lymphocytic-lymphoma-and-b-cell-non-hodgkin-lymphoma
#10
REVIEW
Allison Rosenthal
PURPOSE OF REVIEW: The purpose of this review is to summarize the available literature for the use of small molecule inhibitors in chronic lymphocytic leukemia and B cell non-Hodgkin lymphoma. RECENT FINDINGS: Ibrutinib, idelalisib, and venetoclax are small molecule inhibitors that have revolutionized therapeutic options for patients with CLL, particularly for those with high-risk disease including 17p deletion. These drugs are increasingly finding application in a variety of subtypes of B cell NHL...
April 24, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28421420/the-future-of-targeting-flt3-activation-in-aml
#11
REVIEW
Mark B Leick, Mark J Levis
Internal tandem duplications (ITD) and tyrosine-kinase domain (TKD) mutations of the FMS-like tyrosine-kinase 3 (FLT3) can be found in up to one third of patients with acute myeloid leukemia (AML) and confer a poor prognosis. First discovered 20 years ago, these mutations were identified as viable therapeutic targets, and FLT3 tyrosine-kinase inhibitors (TKIs) have been in development for the last decade with steadily increasing potency. However, FLT3-mutated AML often acquires resistance to the growing armamentarium of FLT3 inhibitors through a variety of mechanisms...
April 18, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28397032/predicting-chemotherapy-resistance-in-aml
#12
REVIEW
Cecilia C S Yeung, Jerald Radich
Acute myeloid leukemia (AML) is the most common type of acute leukemia and is characterized by a wide variety of distinct cytogenetic and molecular subgroups that impact upon response and survival. Despite decades of trials trying to improve short- and long-term responses, outcomes have been stubbornly stable. Thus, the problem of chemotherapy resistance remains unsolved. Indeed, the use of novel targeted agents has uncovered new mechanisms of chemotherapy resistance. In this review, we will cover past work of primary treatment resistance, new resistance mechanisms in de novo AML, functional mechanism of resistance inherent to the leukemic blasts, and resistance mechanisms attributed to host factors and also review acquired mechanisms of resistance...
April 10, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28353016/new-therapeutic-strategies-in-acute-lymphocytic-leukemia
#13
REVIEW
Louise M Man, Amy L Morris, Michael Keng
Most drugs used in standard regimens for acute lymphoblastic leukemia (ALL) were developed more than 30 years ago. Since that time, several new drugs have been developed and incorporated into ALL treatment. In spite of this, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL. This manuscript discusses newer treatment strategies, including purine nucleoside analogs, monoclonal antibodies, antibody drug conjugates, mammalian target of rapamycin (mTOR) inhibitors, proteasome inhibitors, histone deacetylase (HDAC) inhibitors, hypomethylating agents, spleen tyrosine kinase inhibitors, Bruton's tyrosine kinase (BTK) inhibitors, Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors, anti-programmed cell death protein (anti-PD-1) antibodies, mitogen-activated protein kinase (MEK) inhibitors, CXCR4 antagonists, poly (ADP-ribose) polymerase (PARP) inhibitors, and FMS-like tyrosine kinase 3 (FLT3) inhibitors...
March 28, 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28540671/multidisciplinary-management-of-mycosis-fungoides-s%C3%A3-zary-syndrome
#14
REVIEW
Sara Berg, Jennifer Villasenor-Park, Paul Haun, Ellen J Kim
PURPOSE OF REVIEW: Diagnosis and management of mycosis fungoides and Sézary syndrome (MF/SS) require accurate clinicopathological correlation and a multidisciplinary approach. We reviewed major advances in the field regarding diagnostic and prognostic tools as well as skin-directed therapies (SDTs) and systemic agents for MF/SS published in the past 2 years. RECENT FINDINGS: Improved technology (T-cell receptor high-throughput sequencing) and increased multicenter collaboration (Cutaneous Lymphoma International Consortium) have led to diagnostic/prognostic advances...
June 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28353017/treatment-of-young-adults-with-acute-lymphoblastic-leukemia
#15
REVIEW
Ankit Kansagra, Mark Litzow
Young adults with acute lymphoblastic leukemia are a distinctive category of patients, with substantial difference in disease biology and response to therapy; hence, they pose unique challenges and issues beyond those faced by children and older adults. Despite inferior survival compared to children, there is growing evidence to suggest that young adults have improved outcomes when treated with pediatric-based approaches. With better supportive care and toxicity management and multidisciplinary team and approach, we have made great improvement in outcomes of young adults with ALL...
June 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28233150/beyond-anthracyclines-preemptive-management-of-cardiovascular-toxicity-in-the-era-of-targeted-agents-for-hematologic-malignancies
#16
REVIEW
Tarsheen K Sethi, Basak Basdag, Nirmanmoh Bhatia, Javid Moslehi, Nishitha M Reddy
Advances in drug discovery have led to the use of effective targeted agents in the treatment of hematologic malignancies. Drugs such as proteasome inhibitors in multiple myeloma and tyrosine kinase inhibitors in chronic myeloid leukemia and non-Hodgkin lymphoma have changed the face of treatment of hematologic malignancies. There are several reports of cardiovascular adverse events related to these newer agents. Both "on-target" and "off-target" effects of these agents can cause organ-specific toxicity. The need for long-term administration for most of these agents requires continued monitoring of toxicity...
June 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28405921/the-role-of-early-molecular-response-in-the-management-of-chronic-phase-cml
#17
REVIEW
Patrick Harrington, Aytug Kizilors, Hugues de Lavallade
PURPOSE OF REVIEW: Although tyrosine kinase inhibitors (TKIs) spectacularly improve the disease burden and the overall survival of chronic myeloid leukemia patients, early identification of a subset of poor TKI responders has been recognized as a critical goal to prevent disease progression in these patients. We herein review the past and recent evidence on the impact of early response. RECENT FINDINGS: In the recent years, the achievement of an early molecular response (EMR, defined as 3-month BCR-ABL1 transcript <10% IS) has emerged as a useful tool to identify poor-risk patients...
April 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28317082/current-review-on-high-risk-multiple-myeloma
#18
REVIEW
Henry S H Chan, Christine I Chen, Donna E Reece
PURPOSE OF REVIEW: New risk stratification systems and treatment strategies have been introduced in recent years. We aim to provide an overview of these recent changes and summarise these data in a concise article that would be useful for clinicians. RECENT FINDINGS: Apart from clinical stage, disease genetics are now recognised as important prognostic risk factors, and various new cytogenetic changes with negative prognostic impact have been identified. New technologies such as minimal residual disease detection are also playing an important role in prognostic assessment...
April 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28299525/poems-syndrome-an-enigma
#19
REVIEW
Rahma Warsame, Uday Yanamandra, Prashant Kapoor
POEMS syndrome is a paraneoplastic disorder secondary to an underlying plasma cell dyscrasia. By definition, all patients with POEMS syndrome must display polyneuropathy and monoclonal plasma cell disorder. In addition, at least one major criterion (Castleman's disease, sclerotic bone lesions, or vascular endothelial growth factor elevation) and one minor criterion (organomegaly, extravascular volume overload, endocrinopathy, skin changes, papilledema, thrombocytosis, or polycythemia) are required for diagnosis...
April 2017: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/28285435/allogeneic-hematopoietic-cell-transplantation-for-myeloma-when-and-in-whom-does-it-work
#20
REVIEW
Qaiser Bashir, Muzaffar H Qazilbash
The growing list of available therapies for patients with multiple myeloma has resulted in tremendously high response rates and prolonged survival. However, the cure remains elusive. A continued effort at developing strategies to utilize all available treatment modalities in the most effective manner is needed. Allogeneic hematopoietic cell transplantation (allo-HCT) is a robust platform, associated with high response rates, and provides a unique foundation on which immune therapies and novel agents can be employed to improve clinical outcomes...
April 2017: Current Hematologic Malignancy Reports
journal
journal
41232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"